Stay Informed With Our Latest Updates

Royalty Finance Tracker

The Gibson Dunn team has represented clients in royalty finance transactions with a total aggregate value of approximately $8 Billion.

Firm News October 27, 2025

Gibson Dunn Advises Essential Utilities on Merger with American Water Works Company

Gibson Dunn is advising Essential Utilities, Inc. on its merger with American Water Works Company, Inc.

Firm News October 7, 2025

Gibson Dunn Represented JPMorgan in Landmark Financing of 3G Capital’s $9.4 Billion Skechers Acquisition

Gibson Dunn advised JPMorgan and the other arrangers and lenders on Beach Acquisition Bidco, LLC’s $4.405 billion credit facilities, comprising a $1.555 billion term loan B facility, a €1.25 billion term loan B facility, and a $1.6 billion multicurrency revolving credit facility, to finance, in part, the approximately $9.4 billion acquisition of Skechers U.S.A., Inc. by 3G Capital

Firm News August 27, 2025

Gibson Dunn Advised Ad Hoc Group of Lenders in City Brewing’s Strategic Debt Reduction and Investment Transaction

Gibson Dunn advised an ad hoc group of lenders in connection with City Brewing Company LLC’s fully consensual strategic transaction to reduce its debt and secure new capital investment.

Firm News August 11, 2025

Gibson Dunn Advises Arrowhead Pharmaceuticals on Asset Purchase Agreement Between Sanofi and Visirna Therapeutics

Gibson Dunn is advising Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran in Greater China

Firm News July 3, 2025

Gibson Dunn Represented HealthCare Royalty and Blue Owl Capital in Acquisition of BridgeBio Pharma’s Royalty Interest in Bayer’s BEYONTTRA®

Gibson Dunn advised HealthCare Royalty and Blue Owl Capital on their acquisition from BridgeBio Pharma of its royalty interest in Bayer’s BEYONTTRA® for $300 million. 

Webcasts May 12, 2025

Gibson Dunn and BCLT Host a Webcast Series on Royalty Finance, the UCC, and Issues of Recharacterization

In a three-part virtual series, BCLT & Gibson Dunn have partnered to discuss issues originally raised in a Law 360 article written by Gibson Dunn attorneys, Todd Trattner and Ryan Murr, entitled How Biotech Cos. Can Utilize Synthetic Royalty Financing.

Firm News October 7, 2024

Gibson Dunn Advises Veritas Capital on $1.2 Billion Financing of its Acquisition of NCR Voyix Digital Banking Business

Gibson Dunn represented Veritas Capital on the $1.2 billion of financing in connection with its $2.45 billion acquisition of NCR Voyix Corporation's cloud-based digital banking business.